摘要
非酒精性脂肪肝(Non alcoholic fatty liver disease,NAFLD)是由多种原因引起的以弥漫性肝细胞大泡性脂肪变为特征的病理综合征,对患者肝功能造成严重损伤,影响着患者的工作和生活,近年来针对NAFLD发病机制的治疗药物不断涌现,为NAFLD患者的治疗提供了更多选择,因此本文就NAFLA的发病机制及治疗药物做一综述。
Non-alcoholic fatty liver disease(NAFLD)is a pathological syndrome characterized by diffuse hepatic bullous steatosis caused by various reasons,which causes severe damage to the liver function and affects the work and life.In recent years,therapeutic drugs targeting the pathogenesis of NAFLD have emerged,providing more options for the treatment of NAFLD,Therefore,this article reviews the pathogenesis of NAFLA and therapeutic drugs.
作者
叶子昊
祝可欣
贺宇涵
何栋升
张景正
YE Zihao;ZHU Kexin;HE Yuhan(School of Pharmacy,Jiangsu Health Vocational College,Jiangsu,Nanjing 211800,China)
出处
《河北医药》
CAS
2023年第22期3484-3488,共5页
Hebei Medical Journal
基金
江苏省大学生创新创业计划项目(编号:202014255002Y),江苏卫生健康职业学院院级重点课题项目(编号:JKB2021005)。
关键词
非酒精性脂肪肝
研究进展
发病机制
潜在药物
non-alcoholic fatty liver disease
research progress
pathogenesis
potential drugs
